Howard Financial Services LTD. Boosts Holdings in Pfizer Inc. (NYSE:PFE)

Howard Financial Services LTD. lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 4.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,221 shares of the biopharmaceutical company’s stock after buying an additional 511 shares during the period. Howard Financial Services LTD.’s holdings in Pfizer were worth $383,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in PFE. Olistico Wealth LLC purchased a new stake in shares of Pfizer in the 2nd quarter valued at approximately $25,000. MFA Wealth Advisors LLC acquired a new stake in Pfizer in the 2nd quarter valued at approximately $29,000. Quarry LP purchased a new stake in Pfizer in the second quarter valued at approximately $31,000. Creekmur Asset Management LLC purchased a new position in shares of Pfizer during the fourth quarter worth $32,000. Finally, Trivant Custom Portfolio Group LLC grew its stake in shares of Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of Pfizer stock opened at $29.22 on Wednesday. The stock has a market capitalization of $165.58 billion, a price-to-earnings ratio of -486.33, a PEG ratio of 1.23 and a beta of 0.67. The firm’s fifty day simple moving average is $29.09 and its 200-day simple moving average is $28.35. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $33.92.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same period in the previous year, the business posted $0.67 earnings per share. Pfizer’s quarterly revenue was up 2.1% on a year-over-year basis. As a group, equities analysts forecast that Pfizer Inc. will post 2.66 earnings per share for the current year.

Analysts Set New Price Targets

PFE has been the subject of a number of research analyst reports. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Thursday, October 3rd. Barclays increased their target price on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Finally, UBS Group lifted their target price on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and an average target price of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.